SRTS (Sensus Healthcare) Research & Development: $6.76 Mil (TTM As of Mar. 2026)


SRTS Sensus Healthcare Inc SRTS
76 GF Score
Price $3.03
GF Value $2.85
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Sensus Healthcare Research & Development?

Sensus Healthcare SRTS +10.58% 76 Research & Development is $6.76 Mil as of Mar. 2026. GuruFocus rates SRTS with a GF Score™ of 76/100 and a GF Value™ of $2.85 (Fairly Valued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Sensus Healthcare's Research & Development for the three months ended in Mar. 2026 was $1.59 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $6.76 Mil.

Sensus Healthcare  (NAS:SRTS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Sensus Healthcare Research & Development Related Terms

Sensus Healthcare Research & Development Historical Data

* Premium members only.

The historical data trend for Sensus Healthcare's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sensus Healthcare Research & Development Chart

Sensus Healthcare Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.44 3.46 3.68 4.22 7.78

Sensus Healthcare Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.61 1.47 1.82 1.88 1.59
SRTS
76GF Score
Sensus Healthcare Inc SRTS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sensus Healthcare Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.76 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $6.76 Mil mean?
Sensus Healthcare (SRTS) has a Research & Development of $6.76 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Sensus Healthcare and its competitors.
Is Sensus Healthcare's Research & Development too high?
Sensus Healthcare's current Research & Development is $6.76 Mil. Overall, Sensus Healthcare has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sensus Healthcare's Research & Development compare to ELUT and COCH?
Sensus Healthcare's Research & Development of $6.76 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Sensus Healthcare and its competitors. Sensus Healthcare's current Research & Development is $6.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sensus Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sensus Healthcare (SRTS) is currently considered Fairly Valued. The stock's GF Value™ is $2.85, compared to a current price of $3.03 — trading 6.3% above its estimated fair value. The current Research & Development is $6.76 Mil. Sensus Healthcare's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Sensus Healthcare (SRTS), the current Research & Development is $6.76 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sensus Healthcare (SRTS) Overvalued in 2026?

Based on GuruFocus' analysis, Sensus Healthcare stock appears to be overvalued. The current stock price of $3.03 is trading 6.3% above its estimated GF Value™ of $2.85. GuruFocus considers Sensus Healthcare to be Fairly Valued.

Key valuation signals for SRTS:

  • Research & Development: $6.76 Mil
  • GF Value™: $2.85 vs. price of $3.03 (6.3% above fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the SRTS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sensus Healthcare Business Description

Other Exchanges 5TX:Germany
Address 851 Broken Sound Parkway, NW, Suite 215, Boca Raton, FL, USA, 33487
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
76GF Score

Get the complete analysis for SRTS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.03
Price
$2.85
GF Value